A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
Completed · Phase 3 · NCT03053440
Conditions: Waldenström's Macroglobulinemia
At a glance
- Research payments reported, 2025
- $4,843
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 201
About the trial
- Sponsor
- BeiGene
- Tested
- BGB-3111 (drug), Ibrutinib (drug)
- Dates
- Started 2017-01-25; completion 2022-06-21
- Results posted
- Yes
This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
From ClinicalTrials.gov, last updated 2024-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $4,843 in research payments for this study in 2025 (1 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.